» Articles » PMID: 34988757

Long-term Results of the Safety and Effectiveness of a Novel Microshunt in Japanese Patients with Primary Open-angle Glaucoma

Overview
Specialty Ophthalmology
Date 2022 Jan 6
PMID 34988757
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the long-term safety and effectiveness of the Preserflo MicroShunt in Japanese primary open-angle glaucoma (POAG) patients.

Study Design: Single-site, nonrandomized observational study.

Patients And Methods: Eight eyes of 7 POAG patients were included. The surgical complications and interventions were monitored. The preoperative and postoperative intraocular pressures (IOPs), numbers of antiglaucoma medications, logarithm of the minimum angle of resolution visual acuity (VA), mean deviation (MD) slope, and corneal endothelial cell density (CECD) were compared retrospectively.

Results: The mean follow-up period was 68.9 months (range, 48-76 months). The baseline IOP of 17.9 ± 3.5 mmHg and the number of glaucoma medications of 3.5 ± 0.5 were significantly reduced at subsequent follow-up visits. At 1, 2, 3, 4, 5, and 6 years postoperatively, the IOPs were 13.8 ± 2.9, 12.8 ± 2.3, 12.1 ± 3.2, 12.6 ± 2.5, 12.3 ± 1.0, and 13.5 ± 3.1 mmHg, respectively, with the use of 1.6 ± 1.4, 1.6 ± 1.6, 1.5 ± 1.4, 1.5 ± 1.4, 1.9 ± 1.3, and 2.0 ± 1.1 medications. Postoperative transient hyphema occurred in 1 eye. Postoperative needling was required in 5 eyes, 12 times in total. No eyes showed significant VA decline, except for 1 eye with a severe central visual field defect that existed preoperatively. The preoperative MD slope of - 1.6 ± 1.2 dB/year improved significantly, to - 0.3 ± 0.2 dB/year (P = 0.023), postoperatively. The baseline CECD decreased from 2595 ± 292 to 2478.4 ± 255 postoperatively.

Conclusion: The microshunt surgical procedure is safe and effective for Japanese POAG patients.

Citing Articles

Preserflo-MicroShunt: Postoperative Effects on Endothelial Cell Density and Corneal Thickness.

Dierse S, Esser E, Merte R, Al-Nawaiseh S, Leclaire M, Eter N Biomedicines. 2025; 13(2).

PMID: 40002777 PMC: 11852638. DOI: 10.3390/biomedicines13020364.


Short-term efficacy and safety of PreserFlo MicroShunt in Japanese patients with medically treated primary open-angle glaucoma.

Suzuki H, Sakata R, Yamae T, Ishiyama Y, Sugimoto K, Saito H Jpn J Ophthalmol. 2025; .

PMID: 39826074 DOI: 10.1007/s10384-024-01159-y.


One-Year Comparison of Efficacy and Safety of PreserFlo MicroShunt with Mitomycin C Applied by Sub-Tenon Injection Versus Sponge.

Majtanova N, Takacova A, Kurilova V, Hejsek L, Majtan J, Kolar P Ophthalmol Ther. 2024; 14(1):153-167.

PMID: 39576486 PMC: 11724825. DOI: 10.1007/s40123-024-01074-y.


Transient hyphema associated with PRESERFLO MicroShunt surgery using a double-step knife in patients with glaucoma.

Sakata R, Aihara M, Shirato S Sci Rep. 2024; 14(1):28457.

PMID: 39558143 PMC: 11574313. DOI: 10.1038/s41598-024-80093-y.


A short-term comparison of surgical results between an ab-externo microshunt and trabeculectomy with a main focus on postoperative corneal astigmatism.

Hamazaki H, Kaiya R, Kaiya T, Hasegawa S, Yamamoto T Jpn J Ophthalmol. 2024; 68(5):562-570.

PMID: 39207651 DOI: 10.1007/s10384-024-01105-y.